The Covid sales boom is over for Pfizer
By Paul R. La Monica, CNN Pfizer generated nearly $57 billion in combined sales last year from its Comirnaty Covid-19 vaccine and Paxlovid antiviral pill. That works out to almost 60% of the company’s total revenue for 2022. But the boom appears to be over. Pfizer told Wall Street Tuesday that it expects Covid-related sales
Continue Reading